Tadalafil
Product Images NDC 45865-218

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 45865-218). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

218 (45865 218)

Tadalafil Tablets 20mg prescription label indicates the product is generic for Cialis with a package size of 30 tablets. The label states each tablet contains 20mg of tadalafil. Manufactured by Ajanta Pharma USA Inc., Bridgewater, NJ, and distributed by Medsource Pharmaceuticals, Rancho Santa Margarita, CA. Safety and usage instructions include headache warnings and physician direction.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph showing the change from baseline in IPSS Total Score over a 12-week treatment duration comparing Tadalafil 5 mg and placebo. The graph indicates a greater decrease in IPSS score with Tadalafil 5 mg across the 12 weeks, with a statistically significant difference at week 12 (p<0.01).*

FDA Label Image

Figure1 (Tadalafil Figure1)

A set of four line graphs depicting the change in blood pressure over time in hours (0 to 96) comparing tadalafil minus placebo. The graphs show Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP, with differences measured in mmHg along the vertical axis and time in hours along the horizontal axis.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs showing the effects on standing and supine systolic blood pressure (mmHg) over 24 hours post-dose. The top graph compares Tadalafil 20 mg plus doxazosin 8 mg with placebo plus doxazosin 8 mg on standing systolic blood pressure. The bottom graph shows similar comparisons for supine systolic blood pressure over the same time period.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph comparing systolic blood pressure changes (mmHg) over 12 hours after administration of tadalafil or placebo, alongside doxazosin. The graph includes four lines representing different time points and treatment combinations, showing blood pressure trends after dosing at 08:00 or 20:00 hours.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days. Concentration decreases over time, with higher initial levels for the 20-mg dose and sustained levels after once-daily dosing.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph depicting the change from baseline in IPSS Total Score over a 12-week treatment duration. The graph compares Tadalafil 5 mg (solid line with circles) versus placebo (dashed line with triangles), showing a greater decrease in score for Tadalafil. Statistical significance is indicated with p<0.01.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment duration for Tadalafil 5 mg versus placebo. The graph shows a greater decrease in score for Tadalafil 5 mg with statistically significant difference indicated (p<0.01).*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph depicting the Least Squares Mean change from baseline over 26 weeks of therapy. The graph compares Tadalafil/Finasteride versus Placebo/Finasteride, showing the difference in effects at week 0, 4, 12, and 26, with markers indicating statistical significance (p<0.001 and p<0.05).*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure of the active ingredient Tadalafil shown as a molecular diagram with rings and bond connections. The structure depicts the characteristic fused ring system and functional groups of Tadalafil, a pharmaceutical compound by Medsource Pharmaceuticals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.